Evommune Inc. (EVMN) vs SAB Biotherapeutics, Inc. (SABS)

Evommune Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Evommune Inc. and SAB Biotherapeutics, Inc. are of similar size ($309.9M and $304.8M). Across the 10 metrics below, SAB Biotherapeutics, Inc. leads on 6 and Evommune Inc. on 4.

Valuation

Metric EVMN SABS Biotechnology median
P/E n/m n/m 7.88
P/S n/m 161.23 11.47
P/B 1.10 1.22 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 100.03 10.73
Earnings yield (130.22%) (19.45%) (28.84%)
Free cash flow yield (24.39%) (21.89%) (23.03%)

Profitability

Metric EVMN SABS Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (141.99%) (19.21%) (57.72%)
Return on assets (62.71%) (16.24%) (49.22%)
Return on invested capital (82.46%) (38.97%) 0.00%

Growth

Metric EVMN SABS Biotechnology median
Revenue growth (TTM) — (60.26%) 5.64%
EPS growth (last fiscal year) 75.23% 78.53% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — (26.69%) 0.00%

Health

Metric EVMN SABS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 11.68 9.22 4.73
Net debt to EBITDA 1.87 2.03 0.96

Dividend

Metric EVMN SABS Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric EVMN SABS Biotechnology median
Market cap 309.93m 304.80m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack